Seattle Genetics is among the majority of the companies making interesting discoveries in the field of cancer research. Dr. Siegall, CEO of Seattle Genetics, has been ardent on enhancing treatment for cancer patients since starting his career in biomedical studies. He has led this innovative company for approximately two decades. Dr. Siegall’s hardwork and determination has greatly contributed to advancements in cancer research and therapies for cancer patients.
Siegall amassed many professional accomplishments since getting his Ph.D. in Genetics from George Washington University. His career started as a senior research investigator at the Bristol-Myers Squibb Pharmaceuticals Research Institute. Before becoming the staff and biotechnology fellow at the National Cancer Institute, he was promoted to being the principal scientist.
Seattle Genetics developed the first antibody-drug conjugates (ADCs) and ADCETRIS, which got approved by FDA in 2011. Currently, ADCETRIS is now available to cancer patients in more than 60 countries around the world. Siegall helped to fundraise over $1.2billion in both public and private funding. The funds were to finance Seattle Genetics in paving way for advanced cancer treatments using innovative technology.
Dr. Siegall was awarded the University of Maryland Alumnus of the Year for Math, Computer and Natural Sciences in 2013. In 2012, he was named the Pacific Northwest Ernst & Young Entrepreneur of the Year. These awards were meant to recognize his significant contributions to the medical and scientific communities. Siegall currently hold 15 patents and continues to search for new ways in medical research. He has published over 70 scientific articles and still shares his knowledge with the medical and scientific communities.
Clay Siegall is an enthusiast of science and technology. In 1998, he co-founded Seattle Genetics. Currently, he is the president, CEO and chairman of the board at Seattle Genetics. The company is growing since their stock price tripled in a span of 5 years. This growth is all because of Clay’s interest in drug development, scientific innovations, research and importantly helping patients.
The Seaport World Trade Center’s Pegs Boston interviewed Siegall concerning the future he envisioned for Seattle Genetics. He said that the company had made a couple of drugs SGN-CD33A and SGN-CD19A. The drugs are designed to target Leukemia cells and stabilize the bloodstream to enable the flushing out of cytotoxic agents.